Mangoceuticals, Inc.
MGRX
$0.36
$0.026.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -18.88% | -25.96% | -38.18% | -40.48% | -39.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.88% | -25.96% | -38.18% | -40.48% | -39.51% |
| Cost of Revenue | -8.83% | -12.84% | -41.20% | -44.50% | -33.04% |
| Gross Profit | -26.26% | -34.11% | -36.05% | -37.59% | -43.51% |
| SG&A Expenses | 87.16% | 108.21% | 108.10% | 36.51% | 1.05% |
| Depreciation & Amortization | 55.59% | 55.59% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.66% | 100.70% | 110.98% | 41.26% | 6.91% |
| Operating Income | -88.32% | -110.17% | -124.88% | -49.96% | -11.68% |
| Income Before Tax | -71.81% | -137.09% | -112.54% | -55.63% | -23.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.81% | -137.09% | -112.54% | -55.63% | -23.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -63.64% | -50.00% | 12.50% | 166.67% | -- |
| Net Income | -71.83% | -137.11% | -112.55% | -55.63% | -23.94% |
| EBIT | -88.32% | -110.17% | -124.88% | -49.96% | -11.68% |
| EBITDA | -95.83% | -108.48% | -101.34% | -26.51% | 2.26% |
| EPS Basic | 61.83% | 46.16% | 48.27% | 45.76% | 40.31% |
| Normalized Basic EPS | 63.88% | 49.04% | 48.73% | 49.16% | 43.18% |
| EPS Diluted | 61.83% | 46.16% | 48.27% | 45.76% | 40.31% |
| Normalized Diluted EPS | 63.88% | 49.04% | 48.73% | 49.16% | 43.18% |
| Average Basic Shares Outstanding | 375.75% | 406.85% | 332.52% | 237.73% | 119.36% |
| Average Diluted Shares Outstanding | 375.75% | 406.85% | 332.52% | 237.73% | 119.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |